This study reports on rates of invasive treatment for cardiogenic shock before and after exclusion from public reporting in New York was implemented and compares these findings with rates in other states without public reporting.
This study examines the effects of a public reporting exclusion policy on the change on rates of revascularization and mortality for patients with acute myocardial infarction complicated by cardiogenic shock in New York vs comparative states without public reporting.
This study investigates changes in the findings of TRANSLATE-ACS, a cohort study comparing the safety and efficacy of prasugrel vs clopidogrel after PCI, when the study data are reanalyzed using instrumental variables vs the investigators’ original inverse probability treatment weighting approach.
This 2-state Markov model estimates the cost-effectiveness of sacubitril/valsartan vs enalapril to treat patients with heart failure.
This secondary analysis of a randomized clinical trial assesses the effects of apixaban doses in patients with atrial fibrillation and 1 dose-reduction criterion.
This cohort study uses administrative claims data to describe use of anticoagulation for atrial fibrillation during sepsis and to compare risk of stroke and bleeding with vs without anticoagulation.
This study uses published GWAS data and mendelian randomization analysis to compare measures of association between lipid fractions (LDL, HDL, triglycerides) and coronary artery disease vs diabetes.
This analysis of 2 population-based surveys examines the differences in recommendations regarding statin therapy between the American College of Cardiology/American Heart Association guidelines for the management of cholesterol and the European Society of Cardiology/European Atherosclerosis Society guidelines.
This study evaluates the overlap between the American College of Cardiology/American Heart Association and European Society of Cardiology guideline recommendations and available evidence from randomized clinical trials for statin use in primary prevention of cardiovascular disease.
This study quantifies the projected gains for deaths prevented or postponed with comprehensive implementation of angiotensin receptor neprilysin inhibition therapy for patients in the United States with heart failure and reduced ejection fraction.
This study uses UNOS data to compare listings for heart, liver, and kidney transplantation before and after implementation of the Affordable Care Act in states that did or did not adopt Medicaid expansion.
This Viewpoint discusses several large trials that have evaluated the efficacy and safety of more intensive antiplatelet strategies for long-term prevention of major adverse cardiovascular events.
This Viewpoint argues against extending dual antiplatelet therapy for more than 1 year after myocardial infarction based on a subgroup analysis of PEGASUS-TIMI 54 trial data.
In this narrative review, Eugene Braunwald and colleagues summarize recent advances in understanding the pathophysiology, diagnosis, treatment, and prognosis of patients with acute coronary syndrome.
This commentary discusses a study published in JAMA describing the accuracy of a decision rule for predicting benefits and risks of continuing dual antiplatelet therapy >1 year after PCI.
A 71-year-old man with nonischemic cardiomyopathy and an LVEF <20% developed ST elevation in leads v4-6 after successful PCI for right coronary artery occlusion. What would you do next?
This Clinical Guideline Synopsis summarizes a 2016 ACC/AHA focused guideline update on duration of dual antiplatelet therapy in patients with coronary artery disease.
Create a personal account or sign in to: